Save The Date - MASCC/ISOO 2015 Cancer Care Meetingmascc2015.kenes.com/PublishingImages/scientific-information... · CHAIRMEN: Mario Dicato (Luxembourg) and Bernardo Rapoport (South

Save The Date

SCIENTIFIC PROGRAMME SORTED BY SESSION TYPE

25 PARALLEL SESSIONS INCLUDING 4 PROFFERED PAPERS SESSIONS

PARALLEL SESSION NUMBER 1

CHAIRMEN: Hans Petter Eikesdal (Norway) and Fausto Roila (Italy)

ROOM CAPACITY: Large TIME: Friday 09:00-10:30 DURATION OF SESSION: 90 min

NAME OF SESSION PRESENTATION TITLE Minutes SPEAKER

Endocrine issues in cancer Introduction 2 min Fausto Roila Italy

Obesity, diabetes and cancer outcome 25 + 5 min Pamela Goodwin Canada

Hypothyroidism after radiotherapy 15 + 5 min Marianne F Rønjom Denmark

Endocrine disorders following treatment with tyrosine kinase inhibitors 20 + 5 min Fausto Roila Italy

Abstract 25-4-O INCIDENCE OF DIABETES INDUCED BY HIGH-DOSE GLUCOCORTICOID TREATMENT IN CANCER PATIENTS

7 + 3 min Helga Schultz Denmark

Conclusion 3 min Hans Petter Eikesdal Norway

PARALLEL SESSION NUMBER 2 CHAIRMEN: Dorothy Keefe (Australia) and Birgitte Grube (Denmark)

ROOM CAPACITY: Medium TIME: Friday 09:00-10:30 DURATION OF SESSION: 90 min


Use of E-Health in Supportive Care Introduction 3 min Dorothy Keefe Australia

E-Health is empowered health Nurses experience

20 + 5 min Bodil Westman Sweden

How can e-health increase adherence to cancer therapy and supportive care? Physicians experience

20 + 5 min Dorothy Keefe Australia

E-health Patients experience

20 + 5 min Jane Pelouchova Czech Republic

Abstract 04-1-O WEB-SUPPORTED INFORMATION NEEDS OF CAREGIVERS IN HEMATOLOGIC CANCER

7 + 3 min G Yigit Turkey

Conclusion 2 min Birgitte Grube Denmark

PARALLEL SESSION NUMBER 3 CHAIRMEN: Patrick Combrez (Belgium) and Lars Kjeldsen (Denmark)



Best Supportive Care in Patients with Haematological Malignancies

Introduction 2 min Patrick Crombez Belgium

Supportive Care in Haematology 15 min Lars Kjeldsen Denmark

General Management of Neutropenic Patients 15 min Patrick Crombez Belgium

Nursing Evidence and Controverses in Infection Prevention 15 min Arno Mank The Nether- lands

Outpatient Bone Marrow Transplantation 15 min William Hogan USA

Abstract 08-2-O RISK OF HYPONATRAEMIA IN CANCER PATIENTS TREATED WITH TARGETED THERAPIES: A META-ANALYSIS OF CLINICAL TRIALS.

7 + 3 min Rossana Berardi Italy

Panel discussion 15 min All

Conclusion 3 min Lars Kjeldsen Denmark

PARALLEL SESSION NUMBER 4 CHAIRMEN: Christoffer Steer (Australia) and Trine Lembrecht Jørgensen (Denmark)



Supportive Care in the Elderly Introduction 2 min Trine Lembrecht Jørgensen Denmark

Is Cancer Symptom Control Any Different in Older Adult Cancer Patients?

20 + 2 min Aminah Jatoi USA

Pain control in the elderly 20 + 2 min Eduardo Bruera USA

Nursing Facilities and Cancer Supportive Care: Providing Best Practices Clinical Services To Older Adult Cancer Patients

20 + 2 min Bente Appel Esbensen Denmark

Abstract 07-1-O INPUT OF A PHARMACIST-LED MEDICATION EVALUATION IN THE MANAGEMENT OF OLDER PATIENTS WITH CANCER

7 + 3 min Myriam Aitichou France

Abstract 07-2-O CHARLSON COMORBIDITY INDEX AS A PREDICTOR OF OVERALL SURVIVAL FOR PATIENTS WITH EARLY STAGE NSCLC?

7 + 3 min Stefan S Jeppesen Denmark

Chairman’s conclusion 2 min Christoffer Steer Australia

PROFFERED PAPERS - PARALLEL SESSION NUMBER 5 CHAIRMEN: Sebastiano Mercadante (Italy) and Svend Ottesen (Denmark) ROOM CAPACITY: Medium TIME: Friday 09:00-10:30 DURATION OF SESSION: 90 min


Psychooncology and Quality of Life Introduction 1 min Svend Ottesen Denmark

18-1-O CANCER CAREGIVER QUALITY OF LIFE: NEED FOR TARGETED INTERVENTION

8 + 3 min Maria Lapid USA

18-2-O EXPECTATION EFFECTS IN ENDOCRINE TREATMENT OF BREAST CANCER: A TWO-YEAR PROSPECTIVE CLINICAL COHORT STUDY

8 + 3 min Yvonne Nestoriuc Germany Young Investigator Winner

18-3-O ESTROGEN RECEPTOR ALPHA (ESR1) GENETIC POLYMORPHISMS AND THE RISK OF CHEMOTHERAPY-ASSOCIATED COGNITIVE IMPAIRMENT IN EARLY-STAGE BREAST CANCER (ESBC) PATIENTS

8 + 3 min Terence Ng Singapore Outstanding Young Investigator

18-4-O RELATIONSHIP BETWEEN SUBJECTIVE AND ACTIGRAPHY-MEASURED SLEEP IN 237 PATIENTS WITH METASTATIC COLORECTAL CANCER (MCC)

8 + 3 min Oxana Palesh USA

18-5-O THE CONTRIBUTION OF INFORMAL CAREGIVERS IN CANCER CARE, AND PATIENT FACTORS ASSOCIATED WITH CAREGIVER OUTCOMES

8 + 3 min Anna Ugalde Australia

22-1-O QUALITY OF LIFE IN ELDERLY/FRAIL PATIENTS WITH GLIOBLASTOMA MULTIFORME: RESULTS OF THE IAEA RANDOMIZED PHASE III STUDY COMPARING SHORT AND STANDARD COURSE OF RADIOTHERAPY

8 + 3 min Elena Fidarova Austria

22-2-O VALIDATION OF THE EORTC QLQ-INFO 25 QUESTIONNAIRE IN LEBANESE CANCER PATIENTS: REVEALING A STATE OF BLISSFUL IGNORANCE?

8 + 3 min Samer Tabchi Lebanon

22-3-O CONFLICT, PARENT DISTRESS, FAMILY STRAIN AND HEALTH-RELATED SYMPTOMS IN LONG-TERM SURVIVORS OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)

8 + 3 min I-Chan Huang USA

Conclusion 1 min Sebastiano Mercadante Italy

PARALLEL SESSION NUMBER 6 CHAIRMEN: Marianne Ewertz (Denmark) and Michael Ewer (USA)



Cancer Therapy-Induced Cardio-Pulmonary Toxicity

Introduction 1 min Marianne Ewertz Denmark

Cardiotoxicity induced by chemotherapy and targeted therapy 35 + 4 min Michael Ewer USA

Pulmonary toxicity induced by chemotherapy and targeted agents 25 + 4 min Richard Gralla USA

Abstract 26-5-O PRIMARY VERSUS SECONDARY CARDIOTOXICITY OF ANTI-CANCER TREATMENT: A DISTINCTION WITH BROAD IMPLICATIONS

7 + 3 min Michael Ewer USA

Abstract 24-6-O RISK OF CARDIOVASCULAR DISEASE AMONG CANCER SURVIVORS AND AGE- AND GENDER-MATCHED CONTROLS

7 + 3 min Dounya Schoormans The Netherlands

Conclusion 1 min Marianne Ewert Denmark

PARALLEL SESSION NUMBER 7 CHAIRMEN: Siri Beier Jensen (Denmark) and Deborah P. Saunders (Canada)



Oral Care in Head and Neck Cancer Introduction 2 min Siri Beier Jensen Denmark

Translating MASCC/ISOO research into patient-centered care: Multidisciplinary phased oral care for patients undergoing head and neck radiation

25 + 3 min Deborah P. Saunders Canada

Focus on taste disturbances 15 + 2 min Anna Boltong Australia

Focus on nutrition 15 + 2 min Harriet Jager-Wittenaar The Netherlands

Abstract 15-1-O STIMULATED RESIDUAL SALIVARY GLAND FUNCTION IS CORRELATED TO MEAN RADIATION DOSE DELIVERED TO THE MAJOR SALIVARY GLANDS DURING RADIOTHERAPY FOR HEAD AND NECK CANCER

10 + 2 min Ruta Zukauskaite Denmark

Abstract 15-2-O ORAL AND DENTAL STATUS IN LONG- TERM SURVIVORS OF ALLOGENEIC HSCT PERFORMED IN CHILDHOOD, ADOLESCENTS OR YOUNG ADULTHOOD -PRELIMINARY RESULTS

10 + 2 min Kristine Eidal Tanem Norway

Concluding remarks 2 min Deborah P. Saunders Canada

PARALLEL SESSION NUMBER 8 Joint session FSK, EONS and MASCC CHAIRMEN: Andreas Charalambous (Cyprus) and Alex Molassiotis (Hong Kong)



Complementary and Alternative Medicine in Cancer Care

Introduction 3 min Alex Molassiotis Hong Kong

CAM in Cancer Care: New data call for mind shifting? 20 min Andreas Charalambous Cyprus

What is the evidence of CAM in cancer patients 20 min Helle Johannessen Denmark

Clinical Use of CAM in Cancer Patients 20 min Alex Molassiotis Hong Kong

Abstract 04-2-O COMPLEMENTARY MEDICINE EDUCATION FOR ONCOLOGY PROFESSIONALS IN ALBERTA: EVALUATION OF AN ONLINE PROGRAM

7 + 3 min Gregory Levin Canada Young Investigator Winner

Discussion 15 min

Conclusion 2 min Andreas Charalambous Cyprus

PARALLEL SESSION NUMBER 9 CHAIRMEN: Jean Jacques Body (Belgium) and Carina Ørts Christensen (Denmark)



Bone Health Introduction 1 min Carina Ørts Christensen Denmark

Prevention of osteoporosis in cancer patients 15 min Jean Jacques Body Belgium

Bone metastases: what is new and what is targeted? 15 min Matti S. Aapro Switzerland

Recognition and management of osteonecrosis of the jaw 15 min Cesar Migliorati USA

Abstract 01-1-O TREATMENT AND PREVENTION OF OSTEONECROSIS OF THE JAW ASSOCIATED WITH MEDICATION:2009-2014

7 + 3 min E. Papadopoulou Greece

Abstract 01-2-O PALLIATIVE SURGICAL INTENT IN THE TREATMENT OF BONE SARCOMAS: A MIDTERM REVIEW FROM A RESOURCE CHALLENGED ENVIRONMENT

7 + 3 min SA Khan India

Abstract 01-3-O RISK OF OSTEOPOROSIS SUBSEQUENT TO CHEMOTHERAPY FOR EARLY-STAGE BREAST CANCER

7 + 3 min Carina Ørts Christensen Denmark

Optimising Bone Health: Discussion 12 min All

Conclusion 2 min Jean Jacques Body Belgium

PROFFERED PAPERS - PARALLEL SESSION 10 CHAIRMEN: Andrea Cheville (USA) and Julie Silver (USA) ROOM CAPACITY: Medium Time: Friday 14.30-16:00 DURATION OF SESSION: 90 min


Rehabilitation and survivorship Introduction 1 min Andrea Cheville USA

24-1-O COMPARING THE COSTS OF THREE PROSTATE CANCER FOLLOW-UP STRATEGIES: A COST-MINIMISATION ANALYSIS

8 + 3 min Alison Pearce Jamaica Young Investigator Winner

24-5-O IMPLEMENTATION OF THE PROSTATE CANCER SUPPORTIVE CARE (PCSC) PROGRAM, A COMPREHENSIVE APPROACH FOR MEN WITH PROSTATE CANCER (PC) AND THEIR PARTNERS

8 + 3 min S L Goldenberg Canada

24-2-O

QUALITY OF LIFE, HEALTH AND PERSONAL WELLBEING UP TO TWO YEARS FOLLOWING CURATIVE INTENT COLORECTAL CANCER SURGERY: RESULTS FROM THE UK COLORECTAL WELLBEING (CREW) STUDY

8 + 3 min Claire Foster United Kingdom

24-3-O PREOPERATIVE ANAEMIA AND BLOOD-TRANSFUSION AS PROGNOSTIC FACTORS FOR MORTALITY IN COLORECTAL CANCER - A SWEDISH COHORT STUDY

8 + 3 min Malin Mörner Sweden

23-7-O IMPROVING ADHERENCE TO CANCER TREATMENT BY ADDRESSING QUALITY OF LIFE IN PATIENTS WITH ADVANCED GASTROINTESTINAL CANCERS

8 + 3 min J Basford Canada

23-3-O IMPACT AND FEASIBILITY OF AN EXERCISE PROGRAM DURING CHEMO-RADIOTHERAPY IN HEAD AND NECK CANCER SURVIVORS:A RANDOMIZED CONTROLLED TRIAL

8 + 3 min Stephen Samuel India Young Investigator Winner

23-4-O INSULIN-LIKE GROWTH FACTORS ARE MODULATED BY EXERCISE IN BREAST CANCER SURVIVORS: A META-ANALYSIS WITH META-REGRESSION

8 + 3 min Jose F M Echávez Colombia

23-6-O SEXUALITY AND SEXUAL FUNCTION ONE YEAR AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

8 + 3 min Kristina Nørskov Denmark

Conclusion 1 min Julie Silver USA

PARALLEL SESSION NUMBER 11

CHAIRMEN: Mario Dicato (Luxembourg) and Bernardo Rapoport (South Africa)



Bone marrow toxicity Introduction 2 min Mario Dicato Luxembourg

Anemia in cancer: an update of the use of iron, EPO and activin receptor antagonists

17 + 3 min Matti Aapro Switzerland

Febrile neutropenia: an update of outpatient management of low risk patients

12 + 3 min Jean Klastersky Belgium

Febrile neutropenia: an update of management of high risk - stem cell transplantation patients

12 + 3 min William Hogan USA

Thrombocytopenia and thrombopoietin 12 + 3 min Mario Dicato Luxembourg

Abstract 26-2-O

INTRAVENOUS IRON ISOMALTOSIDE 1000 (MONOFER®) AS MONO THERAPY IN COMPARISON WITH ORAL IRON SULPHATE IN PATIENTS WITH NON-MYELOID MALIGNANCIES ASSOCIATED WITH CHEMOTHERAPY INDUCED ANAEMIA (CIA)

7 + 3 min G Birgegård Sweden

Abstract 13-1-O BIOSIMILAR FILGRASTIM AND CHEMOTHERAPY-INDUCED NEUTROPENIA: OVERALL RESULTS OF THE NEXT STUDY

7 + 3 min D Kamioner France

Conclusion 3 min Bernardo Rapoport South Africa

PARALLEL SESSION NUMBER 12 CHAIRMEN: Mario Lacouture (USA) and Inge Marie Svane (Denmark)

ROOM CAPACITY: medium TIME: Friday 17:45-19:15 DURATION OF SESSION: 90 min


Novel Therapies and Best Supportive Care in Cutaneous Malignancies

Introduction 5 min Mario Lacouture USA

Efficacy of agents targeting the BRAF/MEK pathway 15 min Peter Arne Gerber Germany

Discussion 5 min

Efficacy of immune checkpoint inhibitors 15 min Inge Marie Svane Denmark

Discussion 5 min

Systemic toxicities from BRAF/MEK pathway and Immune check point inhibitors

15 min Vincent Sibaud France

Discussion 5 min

Dermatologic toxicities from BRAF/MEK pathway and Immune check point inhibitors

15 min Mario Lacouture USA

Discussion 5 min

Conclusion 5 min Inge Marie Svane Denmark

PARALLEL SESSION NUMBER 13 CHAIRMEN: Petra Feyer (Germany) and Marianne Ewertz (Denmark)



Radiotherapy-induced Late Toxicities in Cancer Survivors

Introduction 2 min Marianne Ewertz Denmark

Late Complications Induced by Radiotherapy in Head and Neck Cancer Patients

20 + 5 min Petra Feyer Germany

Carditoxicity induced by radiotherapy 20 + 5 min Sarah C Darby United Kingdom

Gastrointestinal late complications of radiotherapy 20 + 5 min Ann Muls United Kingdom

Abstract 25-3-O

COMPARISON OF BENEFITS, SAFETY OF 8% VERSUS 4% FORMALIN FOR TREATMENT OF CHRONIC HEMORRHAGIC RADIATION PROCTITIS IN PATIENTS OF CERVICAL CARCINOMA: A RANDOMIZED CONTROLLED TRIAL

7 + 3 min Mukesh Singhal India

Conclusion 3 min Petra Feyer Germany

PROFFERED PAPERS - PARALLEL SESSION 14 CHAIRMEN: Paul Hesketh (USA) and Rajesh Lalla (USA) ROOM CAPACITY: Medium TIME: Friday 17:45-19:15 DURATION OF SESSION: 90 min


Gastro-intestinal toxicity Introduction 1 min Paul Hesketh USA

11-2-O ANTIEMESIS PROPHYLAXIS AMONG BREAST CANCER (BC) PATIENTS RECEIVING ANTHRACYLINE-BASED CHEMOTHERAPY: A POPULATION-BASED STUDY.

8 + 3 min Mariana Chavez USA Mac Gregor Young Investigator Winner

11-3-O

EFFICACY AND SAFETY OF ROLAPITANT FOR PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) OVER MULTIPLE CYCLES OF HIGHLY- OR MODERATELY EMETOGENIC CHEMOTHERAPY (HEC; MEC)

8 + 3 min Bernardo Rapoport South Africa

11-4-O ROLE OF OLANZAPINE IN CHEMOTHERAPY INDUCED NAUSEA AND VOMITING ON PLATINUM BASED CHEMOTHERAPY PATIENTS; A RANDOMIZED CONTROLLED STUDY

8 + 3 min

Sandip Mukhopadhyay India

11-5-O THE ORAL ADMINISTRATION OF THE BRAIN PENETRATING GHRELIN AGONIST, HM01, ANTAGONIZES CISPLATIN-INDUCED EMESIS IN SUNCUS MURINUS (HOUSE MUSK SHREW)

8 + 3 min John Rudd Hong Kong

11-6-O SINGLE- VERSUS MULTIPLE-DAY CORTICOSTEROID DOSING FOR DELAYED CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING

8 + 3 min Pamela Ng Canada

10-3-O TIGHT JUNCTION DISRUPTION IS SEEN IN THE ORAL CAVITY OF PATIENTS RECEIVING STANDARD DOSE CHEMOTHERAPY.

8 + 3 min Hannah Wardill Australia

10-4-O DEVELOPMENT AND VALIDATION OF A PATIENT-REPORTED ASSESSMENT TOOL FOR SYSTEMIC THERAPY-INDUCED DIARRHEA

8 + 3 min Michelle Lui Canada

10-5-O ASSOCIATION BETWEEN ORAL MICROBIOME AND MUCOSITIS IN HEMATOPOIETIC STEM CELL TRANSPLANT SUBJECTS

8 + 3 min Farah Mougeot USA

Conclusion 1 min Rajesh Lalla USA

PARALLEL SESSION NUMBER 15 CHAIRMEN: Matti Aapro (Switzerland) and Didier Kamioner (France)

ROOM CAPACITY: Medium TIME: Saturday 10:30-12:00 DURATION OF SESSION: 90 min


MASCC AFSOS Symposium Introduction 2 min Matti Aapro Switzerland

Pharmacist in Cancer Care Unit; A Role for Quality of Care?

10 min Jean Baptiste Rey France

Discussion 5 min

Back Home: Evidence for Supportive Network; how, when and for who ?

10 min Manon Lemonde Canada

Discussion 5 min

Mucositus Guidelines : An Update 10 min RJ Bensadoun France

Discussion 5 min

Breathlessness at the Palliative Time : From Guidelines to Practice

10 min Claudia Mazzocato Switzerland

Discussion 5 min

European Supportive Care Associations in MASCC: from AFSOS to NICSO (Roundtable discussion)

25 min Petra Feyer Germany Carla Ripamonti Italy Ivan Krakowski France

Conclusion 3 min Didier Kamioner France

PARALLEL SESSION NUMBER 16 CHAIRMEN: Karin Olson (Canada) and Eric van Muilekom



Fatigue Introduction 2 min Eric van Muilekom The Netherlands

How do we define fatigue and what is new? 15 + 0 min Karin Olson Canada

Cancer-related sleep disturbances 15 + 5 min Poul Jennum Denmark

Compassion fatigue: How to deal with it? 15 + 5 min Eric van Muilekom The Netherlands

Fatigue in advanced cancer 15 + 5 min Andreas Charalambous Cyprus

Abstract 06-1-O RANDOMIZED TRIAL OF YOGA VERSUS STRENGTHENING EXERCISES IN BREAST CANCER SURVIVORS WITH PERSISTENT FATIGUE

7 + 3 min Daniela Stan USA

Conclusion 3 min Karin Olson Canada

PARALLEL SESSION NUMBER 17 CHAIRMEN: Charles Loprinzi (USA) and Lise Eckhoff (Denmark)



Neurological Complications Introduction 1 min Charles Loprinzi USA

Genomic risks for developing CIPN 20 + 3 min Lise Eckhoff Denmark

Treatment of CIPN 20 + 3 min Charles Loprinzi USA

Evidence-based caring for patients with CIPN 20 + 2 min Anita Margulies Switzerland

Abstract 12-1-O CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN MULTIPLE MYELOMA PATIENTS: INFLUENCE ON QUALITY OF LIFE AND VALIDATION OF A QUESTIONNAIRE FOR DAILY CLINICAL PRACTICE

7 + 3 min Antoinetta Beijers The Netherlands

Abstract 12-2-O CAN PREGABALIN PREVENT PACLITAXEL-ASSOCIATED NEUROPATHY?—A PILOT TRIAL

7 + 3 min Shivani Shinde USA

Conclusion 1 min Lise Eckhoff Denmark

PARALLEL SESSION NUMBER 18 joint session IASLC/MASCC CHAIRMEN: Richard Gralla (USA) and Wilfried Ernst E Eberhardt (Germany)

ROOM CAPACITY: Large TIME: Saturday 10.30-12:00 DURATION OF SESSION: 90 min


Supportive Care in Lung Cancer Introduction 3 min Richard Gralla USA

Management of NSCLC – state of the art 20 min Wilfried Ernst E Eberhardt Germany

Dyspnea – magnitude of the problem and management 15 min Sam Ahmedzai United Kingdom

New options in the management of hyponatremia 10 min Mellar Davis USA

Quality of life in lung cancer 15 min Richard Gralla USA

Abstract 24-4-O OVERALL SURVIVAL AFTER PALLIATIVE THORACIC RADIOTHERAPY FOR LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER NOT SUITABLE FOR CURATIVE INTENDED TREATMENT

7 + 3 min Olfred Hansen Denmark

How to optimize supportive care in lung cancer? 15 min Round table discussion All

Conclusion 2 min Wilfried Ernst E Eberhardt Germany

PARALLEL SESSION NUMBER 19 CHAIRMEN: Sebastiano Mercadante (Italy) and Sam Ahmedzai (United Kingdom)

ROOM CAPACITY: Large TIME: Saturday 13:00-14:30 DURATION OF SESSION: 90 min


Cancer Pain – Opioids and Beyond Introduction 2 min Sebastiano Mercadante Italy

Neuronal mechanisms and targeted therapy of bone cancer pain

20 + 5 min Sam Ahmedzai United Kingdom

Understanding visceral pain - origins and treatments 15 + 5 min Sebastiano Mercadante Italy

Cancer pain at the end of life – rational and realistic management choices

15 + 5 min Eduardo Bruera USA

Abstract 03-1-O EFFICACY, SAFETY, AND TOLERABILITY OF FULRANUMAB AS ADJUNCTIVE THERAPY FOR CANCER-RELATED PAIN: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY

7 + 3 min Neal Slatkin USA

Abstract 03-2-O COMPARISON OF UPPER AND LOWER EXTREMITY CHARACTERIZATIONS OF CHEMOTHERAPY-INDUCED NEUROPATHY (CIN) USING PATIENT REPORTED OUTCOME MEASURES

7 + 3 min Christine Miakowski USA

Conclusion 3 min Sam Ahmedzai United Kingdom

PARALLEL SESSION NUMBER 20 CHAIRMEN: Mario Lacouture (USA) and Jennifer Choi (USA)

ROOM CAPACITY: medium TIME: Saturday 13:00-14:30 DURATION OF SESSION: 90 min


Skin toxicity Introduction 5 min Jennifer Choi USA

Assessment of skin toxicity 20 min Christine Boers-Doets NED

Case 1 (chemotherapy) 5 min Mario Lacouture USA

Discussion 10 min Moderator: Jennifer Choi USA

State of the art: chemotherapy-induced skin toxicity 15 min Mario Lacouture USA

Case 2 (targeted therapy) 5 min Jennifer Choi USA

Discussion 10 min Moderator: Mario Lacouture USA

State of the art: targeted therapy-induced skin toxicity 15 min Jennifer Choi USA

Conclusion 5 min Mario Lacouture USA

PARALLEL SESSION NUMBER 21 CHAIRMEN: Charles Loprinzi (USA) and Tom Møller (Denmark)



Supportive Care in Breast Cancer – the Significance of Life Style

Introduction 1 min Charles Loprinzi Loprinzi USA

Use of Exercise in Patients with Breast Cancer 15 min Tom Møller Denmark

Q & A 5 min

Healthy Diet and Lifestyle for Breast Cancer Patients 15 min Christina Lacerda Portugal

Q & A 4 min

Smoking as an Independent Risk Factor for Radiotherapy- Induced Skin Reactions in Breast Cancer

15 min Lena Sharp Sweden

Q & A 4 min

Abstract 26-3-O RACIAL DIFFERENCES IN EARLY SYMPTOM MANAGEMENT, HOSPICE USE, AND INTENSITY OF END-OF-LIFE CARE AMONG ELDERLY WOMEN WITH BREAST CANCER

7 + 3 min Devon Check USA

Abstract 23-5-O THE EFFECT OF EXERCISE TRAINING ON MEDIATORS OF TUMOUR PROGRESSION IN BREAST CANCER SURVIVORS: A META-ANALYSIS

7 + 3 min Jose F M Echávez Colombia

Abstract 09-1-O STANDARDIZING LYMPHEDEMA ASSESSMENT PRACTICES: A QUALITY IMPROVEMENT INITIATIVE IN ALBERTA CANADA

7 + 3 min Margaret McNeely Canada

Conclusion 1 min Tom Møller Denmark

http://www.sciencedirect.com/science/article/pii/S0960977613002129

http://www.sciencedirect.com/science/article/pii/S0960977613002129

PARALLEL SESSION NUMBER 22 CHAIRMEN: Richard Gralla (USA) and Jørn Herrstedt (Denmark)



Chemotherapy-induced nausea and vomiting

Introduction 2 min Jørn Herrstedt Denmark

Emetic risk classification of antineoplastic agents 15 + 5 min Paul Hesketh USA

Use of antiemetics targeting a single receptor 15 + 5 min Karin Jordan Germany

Use of antiemetics targeting multiple receptors 15 + 5 min David Warr Canada

Use of antiemetics in chemoradiation 12 + 3 min Christina Ruhlmann Denmark

Abstract 11-1-O

IMPACT AND MANAGEMENT OF CHEMOTHERAPY/ RADIOTHERAPY-INDUCED NAUSEA AND VOMITING AND THE PERCEPTUAL GAP BETWEEN ONCOLOGISTS/ONCOLOGY NURSES AND PATIENTS: A CROSS-SECTIONAL MULTINATIONAL SURVEY

7 + 3 min Bahrat Amlani United Kingdom

Conclusion 3 min Richard Gralla USA

PARALLEL SESSION NUMBER 23 CHAIRMEN: Sharon Elad (USA) Ourania Nicolatou-Galitis (Greece)



Mucositis Introduction 2 min

Ourania Nicolatou- Greece Galitis

Update on low level laser therapy for oral mucositis 18 + 4 min Sharon Elad USA

Updates on clinical studies of palifermin for oral and gastrointestinal mucositis

18 + 4 min Nicole M. A. Blijlevens The Netherlands

Stomatitis secondary to targeted anti-cancer agents 18 + 4 min

Ourania Nicolatou- Greece Galitis

Abstract 10-1-O CLONIDINE MUCOADHESIVE BUCCAL TABLET (CLONIDINE LAURIAD) PREVENTS SEVERE RADIOMUCOSITIS IN HEAD AND NECK CANCER PATIENTS: A PHASE II RANDOMIZED TRIAL

7 + 3 min Rene-Jean Bensadoun France

Abstract 10-2-O EFFECTIVENESS OF LOW-LEVEL LASER THERAPY IN THE PREVENTION AND TREATMENT OF CHEMOTHERAPY-INDUCED ORAL MUCOSITIS IN CHILDREN

7 + 3 min Alessandra Majorana Italy

Conclusion 2 min Sharon Elad USA

PARALLEL SESSION NUMBER 24 CHAIRMEN: Andrea Cheville (USA) and Ann-Dorthe Olsen Zwisler (Denmark)



Rehabilitation Introduction 2 min Andrea Cheville USA

Rehabilitation of older adults with cancer 15 + 5 min Christoffer Steer Australia

Lessons to be learned from rehabilitation of non-cancer patients 15 + 5 min Ann-Dorthe Olsen Denmark Zwisler

Optimization of Cancer Rehabilitation 20 + 5 min Andrea Cheville USA

Abstract 23-1-O PATIENT ACTIVATION THROUGH COUNSELING AND EXERCISE – ACUTE LEUKEMIA (PACE-AL) TRIAL – A RANDOMIZED CONTROLLED TRIAL

8 + 3 min Mary Jarden Denmark

Abstract 23-2-O THE MEDIATING ROLE OF PERCEIVED DISABILITY IN THE LONG-TERM IMPACT OF ARM MORBIDITY ON BREAST CANCER SURVIVORS' EMOTIONAL WELL-BEING

8 + 3 min Thomas Hack Canada

Conclusion 1 min Ann-Dorthe Olsen Denmark Zwisler

PARALLEL SESSION NUMBER 25 CHAIRMEN: Declan Walsh (Ireland) and Eduardo Bruera (USA)



Nutrition and cancer cachexia Introduction 1 min Declan Walsh Ireland

14-1-O

SWALLOW ASSESSMENT IN HEAD AND NECK CANCER PATIENTS TREATED WITH MULTI-MODALITY THERAPY: COMPARISON OVER TIME OF SELF-REPORT, PHYSICAL EXAM FINDINGS AND OBJECTIVE MEASURES (R01 CA149113-01A1)

8 + 3 min M Maddalo Italy

14-2-O

DIETARY AND EXERCISE INTERVENTIONS TO IMPROVE QUALITY OF LIFE, METABOLIC RISK FACTORS AND ANDROGEN DEFICIENCY SYMPTOMS IN MEN WITH PROSTATE CANCER UNDERGOING ANDROGEN DEPRIVATION THERAPY

8 + 3 min L Teleni Australia

14-3-O CANCER MALNUTRITION AND CLINICAL OUTCOMES: RESULTS FROM TWO POINT PREVALENCE STUDIES IN AUSTRALIA

8 + 3 min K Marshall Australia

14-4-O EXPLORING POTENTIAL BENEFIT OF EARLIER NUTRITIONAL INTERVENTIONS IN ADULTS WITH UPPER GASTROINTESTINAL CANCER: A RANDOMISED TRIAL

8 + 3 min MA Silvers Australia

02-1-O RESULTS FROM ROMANA 1 AND 2: TWO PHASE III TRIALS OF ANAMORELIN IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH CACHEXIA

8 + 3 min A Abernethy USA

02-2-O RESULTS FROM ROMANA 3: A SAFETY EXTENSION STUDY OF ANAMORELIN IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS WITH CACHEXIA

8 + 3 min D Currow Australia

02-3-O IMPACT OF CANCER CACHEXIA ON THE PHARMACOLOGY AND TOXICITY OF CHEMOTHERAPY (5-FU, PACLITAXEL) AND THE ORAL TYROSINE KINASE INHIBITOR ERLOTINIB: A RETROSPECTIVE PILOT STUDY (CAT)

8 + 3 min

F Strasser Switzerland

02-4-O VALIDATING ASSESSMENT OF SKELETAL MUSCLE MASS (SMM) AT L1 ON CHEST CT SCAN IN EVALUATING CANCER CACHEXIA (CC) AND SARCOPENIA IN PATIENTS WITH LUNG CANCER

8 + 3 min A Recio-Boiles USA

Conclusion 1 min Eduardo Bruera USA

3 PLENARY SESSIONS

PLENARY SESSION NUMBER 1 CHAIRMEN: David Warr (Canada) and Jørn Herrstedt (Denmark)

ROOM CAPACITY: Large TIME: Thursday 12:45-13:45 DURATION OF SESSION: 60 min


Supportive Care is a Continuum Introduction to session and Einhorn 2 min David Warr Canada

Late Toxicities Induced by Anti-Neoplastic Agents; a Half Century Evaluation of Advantages and Challenges

28 min Lawrence H Einhorn USA

Introduction Silver 1 min Jørn Herrstedt Denmark

The Role of Prehabilitation and Rehabilitation in High-Quality Cancer Care

28 min Julie Silver USA

Closure 1 min Jørn Herrstedt Denmark

PLENARY SESSION NUMBER 2 CHAIRMEN: David Warr (Canada) and Marianne Ewertz (Denmark)



Pharmaceutical Supportive Care Introduction to session and Chan 3 min David Warr Canada

Steven Grunberg Award Session Pharmacogenomics in Supportive Care 18 min Alexandre Chan Singapore

Introduction Lassen 1 min Marianne Ewertz Denmark

Unmasking Side Effects from “First-in-Man” Antineoplastic Medicine 18 min Ulrik Lassen Denmark

Introduction Keefe 1 min David Warr Canada

New Developments in Personalised Supportive Care Medicine

18 min Dorothy Keefe Australia

Closure 1 min Marianne Ewertz Denmark

PLENARY SESSION NUMBER 3 CHAIRMEN: Lawrence H Einhorn (USA) and Declan Walsh (IRL)



The Oncologic Tsunami

Introduction to session and Gosney 2 min Declan Walsh Ireland

Older Cancer Patients Survive – are we prepared? 28 min Margot A Gosney United Kingdom

Introduction Olver 2 min Lawrence H Einhorn USA

Reality of Supportive Care in the Developing World 28 min Ian Olver Australia

Closure 1 min Declan Walsh Ireland

3 PRO ET CON SESSIONS

PRO ET CON SESSION NUMBER 1 CHAIRMEN: Alex Chan (Singapore)

ROOM CAPACITY: Medium TIME: Thursday 16:15-17:15 DURATION OF SESSION: 60 min


Antithrombotic agents for every patient with incurable cancer?

Introduction and voting 5 min Alex Chan Singapore

PRO 20 min Mario Dicato Luxemburg

CON 20 min Florian Strasser Switzerland

Discussion and new voting 15 min Alex Chan Singapore

PRO ET CON SESSION NUMBER 2 CHAIRMAN: Sam Ahmedzai (United Kingdom)

ROOM CAPACITY: Large TIME: Thursday 16:15-17:15 DURATION OF SESSION: 60 min


Euthanasia, assisted dying Introduction and voting 5 min Sam Ahmedzai United Kingdom

PRO 20 min Dominique Lossignol Belgium

CON 20 min Gilles Freyer France

Discussion and new voting 15 min Sam Ahmedzai United Kingdom

PRO ET CON SESSION NUMBER 3 CHAIRMAN: Declan Walsh (Ireland)



Parenteral nutrition in advanced cancer

Introduction and voting 5 min Declan Walsh Ireland

PRO 20 min Florian Strassser Switzerland

CON 20 min Eduardo Bruera USA

Discussion and new voting 15 min Declan Walsh Ireland

7 CHALLENGE YOUR EXPERT SESSIONS

CHALLENGE YOUR EXPERT SESSION NUMBER 1 CHAIRMAN: Fausto Roila (Italy) EXPERT: Mellar Davis (USA) ROOM CAPACITY: Medium TIME: Thursday 16:15-17:00 DURATION OF SESSION: 45 min


Management of nausea and vomiting in advanced cancer

Introduction 3 min Fausto Roila Italy

State of the art lecture 25 min Mellar Davis USA

Discussion 15 min All

Conclusion 2 min Fausto Roila Italy

CHALLENGE YOUR EXPERT SESSION NUMBER 2 CHAIRMAN: Eduardo Bruera (USA) EXPERT: Declan Walsh (Ireland)

ROOM CAPACITY: Medium TIME: Thursday 16:15-17:00 DURATION OF SESSION: 45 min


Use of cannabinoids in cancer therapy and supportive care

Introduction 3 min Eduardo Bruera USA

State of the art lecture 25 min Declan Walsh Ireland


Conclusion 2 min Eduardo Bruera USA

CHALLENGE YOUR EXPERT SESSION NUMBER 3 CHAIRMAN: Svend Saalbach Ottesen (Denmark) EXPERT: Eduardo Bruera (USA)



Management of patients with delirium

Introduction 3 min Svend Saalbach Ottesen Denmark

State of the art lecture 25 min Eduardo Bruera USA


Conclusion 2 min Svend Saalbach Ottesen Denmark

CHALLENGE YOUR EXPERT SESSION NUMBER 4 CHAIRMAN: Aminah Jatoi (USA) EXPERT: Florian Strasser (Switzerland)



Nutrition and Cancer Cachexia Introduction 3 min Aminah Jatoi USA

State of the art lecture 25 min Florian Strasser Switzerland


Conclusion 2 min Aminah Jatoi USA

CHALLENGE YOUR EXPERT SESSION NUMBER 5 CHAIRMAN: Mellar Davis (USA) EXPERT: Mario Dicato (Luxembourg)



Cancer and Thrombosis Introduction 3 min Mellar Davis USA

State of the art lecture 25 min Mario Dicato Luxembourg


Conclusion 2 min Mellar Davis USA

CHALLENGE YOUR EXPERT SESSION NUMBER 6 CHAIRMAN: Bernardo Rapoport (South Africa) EXPERT: Jean Klastersky (Belgium)



Fever of Unknown Origin Introduction 3 min Bernardo Rapoport South Africa

State of the art lecture 25 min Jean Klastersky Belgium


Conclusion 2 min Bernardo Rapoport South Africa

CHALLENGE YOUR EXPERTS SESSION NUMBER 7 CHAIRMAN: Fred Ashbury (Canada) EXPERTS: Fred Ashbury (Canada), Paul Hesketh (USA) and Ian Olver (Australia)



How to prepare and submit a paper for Supportive Care in Cancer

Introduction 5 min Fred Ashbury Canada

The editors view 10 min Fred Ashbury Canada

The authors view 20 min Paul Hesketh USA

The reviewers view 20 min Ian Olver Australia


Conclusion 5 min Fred Ashbury Canada

6 PROFFERED PAPERS AND EXPERTS OPINIONS SESSIONS

PROFFERED PAPERS AND EXPERTS OPINIONS 1 CHAIRMEN AND EXPERTS: Dorothy Keefe (Australia) and Mario Lacouture (USA) ROOM CAPACITY: Medium TIME: Thursday 16.15-17:15 DURATION OF SESSION: 60 min


Toxicity of targeted agents Introduction to session and to toxicity of targeted agents 2 min Dorothy Keefe Australia

Abstract 25-1-O META-ANALYSIS: HYPERTENSION RISK IN SELECTED TARGETED AGENTS 8 min Carmelita Escalante USA

Abstract 26-7-O ANTIANGIOGENIC-SPECIFIC ADVERSE EVENTS (AES) IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH NINTEDANIB (N) AND DOCETAXEL (D)

8 min Anders Mellemgaard Denmark

Expert opinion abstracts 25-1-O and 26-5-O 12 min Dorothy Keefe Australia

Skin toxicity Introduction skin toxicity 1 min Mario Lacouture USA

Abstract 20-1-O LOW LEVEL LASER THERAPY FOR THE MANAGEMENT OF RADIATION DERMATITIS: FINAL RESULTS OF THE DERMIS TRIAL, A PILOT STUDY IN BREAST CANCER PATIENTS

8 min Jeroen Mebis Belgium

Abstract 20-2-O PALMAR PLANTAR ERYTHRODYSESTHESIA PREVENTION WITH ATORVASTATIN AND POLYPRENOL

8 min Sergejs Kuznecovs Latvia

Expert opinion abstracts 20-1-O and 20-2-O 12 min Mario Lacouture USA

Closure 1 min Mario Lacouture USA

PROFFERED PAPERS AND EXPERTS OPINIONS 2 CHAIRMEN AND EXPERTS: Fausto Roila (Italy) and Charles Loprinzi (USA) ROOM CAPACITY: Medium TIME: Friday 08:00-08:45 DURATION OF SESSION: 45 min


Bone complications and chemotherapy-induced nausea and vomiting

Introduction 1 min Fausto Roila Italy

Abstract 27-3-O LBA PREVALENCE OF LOW BONE MASS AND OSTEOPOROSIS IN WOMEN DIAGNOSED WITH GYNECOLOGIC CANCER

8 min Beatrice Edwards USA

Abstract 27-2-O LBA

A RANDOMIZED, PHASE 3, DOUBLE-BLIND STUDY OF INTRAVENOUS FOSAPREPITANT AS A SINGLE DOSE FOR PREVENTING HEMOTHERAPY- INDUCED NAUSEA AND VOMITING ASSOCIATED WITH MODERATELY EMETOGENIC CHEMOTHERAPY

8 min Bernardo Rapoport South Africa

Expert opinion abstracts 27-3-O and 27-2-O 12 min Fausto Roila Italy

Neurological complications Introduction 1 min Charles Loprinzi USA

Abstract 27-1-O LBA

PREVENTION OF NEUROPATHY USING CALMANGAFODIPIR (PLEDOX®): RESULTS FROM A PHASE I STUDY AND A PLACEBO-CONTROLLED RANDOMIZED STUDY (PLIANT) IN PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC)

8 min Bengt Glimelius Sweden

Expert opinion abstract 27-1-O 6 min Charles Loprinzi USA

Closure 1 min Charles Loprinzi USA

PROFFERED PAPERS AND EXPERTS OPINIONS 3 CHAIRMEN AND EXPERTS: Florian Strasser (Switzerland) and Alexander Chan (Singapore)

ROOM CAPACITY: Small TIME: Friday 08:00-08:45 DURATION OF SESSION: 45 min


Palliative Care Introduction palliative care 1 min Florian Strasser Switzerland

Abstract 17-1-O A DIAGNOSTIC MODEL FOR IMPENDING DEATH IN PATIENTS WITH ADVANCED CANCER

8 min David Hui USA

Abstract 05-1-O PROGNOSTIC EVALUATION IN PALLIATIVE CARE: FINAL RESULTS FROM A PROSPECTIVE COHORT STUDY

8 min Paola Ermacora Italy

Expert opinion abstracts 17-1-O and 05-1-O 12 min Florian Strasser Switzerland

Abstract 17-2-O CHEMICAL COMPATIBILITY/STABILITY OF COMMONLY USED DRUG COMBINATIONS ADMINISTERED BY CONTINUOUS SUBCUTANEOUS INFUSIONS FOR END OF LIFE CARE

8 min Andrew Dickman United Kingdom

Expert opinion abstract 17-2-O 7 min Alexander Chan Singapore

Closure 1 min Alexander Chan Singapore

PROFFERED PAPERS AND EXPERTS OPINIONS 4 CHAIRMEN AND EXPERTS: Rajesh Lalla (USA) and Alexis Molassiotis (Hong Kong)

ROOM CAPACITY: Small TIME: Friday 16:30-17:30 DURATION OF SESSION: 60 min


Evidence-based guidelines Introduction to session and to development of guidelines 2 min Rajesh Lalla USA

Abstract 19-1-O DEVELOPING AN EVIDENCE-BASED GUIDELINE FOR MANAGEMENT OF DYSPNEA IN CANCER PATIENTS: DESCRIPTION OF MASCC RESPIRATORY STUDY GROUP TASK

8 min Sam Ahmedzai United Kingdom

Abstract 25-2-O

PROACTIVE APPROACH: DEVELOPING AND IMPLEMENTING GUIDELINES FOR TREATING PATIENTS WITH ORALLY-ADMINISTERED ANTI-CANCER DRUGS (OAACD) IN THE HOME-CARE SETTING: EXPERIENCE OF A COMPREHENSIVE CANCER CENTER

8 min Tal Granot Israel

Expert opinion abstracts 19-1-O and 25-2-O 12 min Rajesh Lalla USA

Education Introduction education 1 min Alex Molassiotis Hong Kong

Abstract 04-3-O ONCOLOGY NURSING SOCIETY (ONS) PUTTING EVIDENCE INTO PRACTICE (PEP): SYNTHESIS OF EVIDENCE BASED INTERVENTIONS FOR ADHERENCE TO ORAL AGENTS FOR CANCER

8 min Cynthia Rittenberg USA

Abstract 04-4-O STRENGTHS, WEAKNESSES AND AREAS FOR IMPROVEMENTS: A COMPARATIVE SURVEY OF UNDERGRADUATE PALLIATIVE CARE (PC) EDUCATION ACROSS ALL UK MEDICAL SCHOOLS (MS)

8 min Steven Walker United Kingdom

Expert opinion abstracts 04-2-O and 04-3-O 12 min Alex Molassiotis Hong Kong

Closure 1 min Alex Molassiotis USA

PROFFERED PAPERS AND EXPERTS OPINIONS 5 CHAIRMEN AND EXPERTS: Ian Olver (Australia) and Mellar Davis (USA)

ROOM CAPACITY: Medium DURATION OF SESSION: 60 min TIME: Friday 16:30-17:30


Palliative care Introduction to session and to palliative care 2 min Ian Olver Australia

Abstract 17-3-O EXPLORING THE COMPLEXITIES OF CAREGIVER QUALITY OF LIFE: QUALITATIVE RESULTS FROM A TRIAL OF EARLY PALLIATIVE CARE

8 min Julie McDonald Canada Young Investigator Winner

Abstract 17-4-O DIFFERENCES IN ATTITUDES AND BELIEFS TOWARD CANCER TREATMENTS AT THE END-OF-LIFE BETWEEN HEMATOLOGIC AND SOLID TUMOR ONCOLOGY SPECIALISTS

8 min David Hui USA

Expert opinion abstracts 17-3-O and 17-4-O 12 min Ian Olver Australia

Abstract 17-5-O THE FREQUENCY, CHARACTERISTICS AND OUTCOMES AMONG CANCER PATIENTS WITH DELIRIUM ADMITTED TO AN ACUTE PALLIATIVE CARE UNIT (APCU)

8 min Maxine de la Cruz USA

Abstract 17-6-O SLEEP DISTURBANCE CONTRIBUTES TO CRF IN CANCER PATIENTS WITH ACTIVE DISEASE

8 min Diwakar Balachandran USA

Expert opinion abstracts 04-2-O and 04-3-O 12 min Mellar Davis USA

Closure 2 min Mellar Davis USA

PROFFERED PAPERS AND EXPERTS OPINIONS 6 CHAIRMEN AND EXPERTS: Aminah Jatoi (USA) and Sam Ahmedzai (United Kingdom)



Pediatrics Introduction to session and to pediatrics 2 min Aminah Jatoi USA

Abstract 16-1-O DEVELOPMENT OF CLINICAL PRACTICE GUIDELINES FOR SUPPORTIVE CARE IN CHILDHOOD CANCER IN THE NETHERLANDS – CURRENT VARIATIONS IN SUPPORTIVE CARE PRACTICE

8 min Erik Loeffen The Netherlands

Abstract 16-2-O TOXICITY IS ASSOCIATED WITH AGE AND BODY MASS INDEX IN NOPHO-AML 2004

8 min Ditte Juel A Løhmann Denmark

Expert opinion abstracts 16-1-O and 16-2-O 12 min Aminah Jatoi USA

Patient Care Introduction to care coordination 1 min Sam Ahmedzai United Kingdom

Abstract 26-1-O CARE COORDINATION EXPERIENCE OF PATIENTS WITH COLORECTAL CANCER: A POPULATION BASED STUDY

8 min Ivana Durcinoska Australia

Abstract 26-6-O PATIENT SATISFACTION WITH CANCER-RELATED CARE: LANGUAGE-BASED DIFFERENTIAL ITEM FUNCTIONING.

8 min Jean-Pierre Pascal USA

Expert opinion abstracts 12 min Sam Ahmedzai United Kingdom

Closure 1 min Sam Ahmedzai United Kingdom

1 POSTER DISCUSSION SESSION

POSTER DISCUSSION 1 CHAIRMEN AND EXPERTS: Jean Klastersky (Belgium) and Mario Dicato (Luxembourg) ROOM CAPACITY: Medium TIME: Friday 08:00-08:45 DURATION OF SESSION: 45 min


Febrile neutropenia Introduction febrile neutropenia 1 min Jean Klastersky Belgium

Abstract 13-2-O Practical Application of a Febrile Neutropenia Pre-Printed Order /Algorithm Incorporating the MASCC Index within a Large Regional Emergency Department

3 min Lee Ann Martin Canada

Abstract 13-3-O ASSESSMENT OF A NOMOGRAM FOR PREDICTING SERIOUS COMPLICATIONS IN PATIENTS FROM THE UNIVERSITY OF SALAMANCA HOSPITAL FEBRILE NEUTROPENIA REGISTRY

3 min Ignacio Matos Spain

Abstract 13-4-O NORTHERN IRELAND'S EXPERIENCE OF IMPROVING INITIAL NEUTROPENIC SEPSIS MANAGEMENT THROUGH A MULTIDISCIPLINARY INTEGRATED CARE PATHWAY

3 min Caroline Forde United Kingdom

Discussion abstracts 13-2-O, 13-3-O and 13-4-O 12 min Jean Klastersky Belgium

Anemia and thrombosis Introduction anemia and thrombosis 1 min Mario Dicato Luxembourg

Abstract 08-1-O TRAJECTORY OF HEMOGLOBIN LEVEL DURING TREATMENT OF SELECTED MYELOSUPPRESSIVE CHEMOTHERAPY REGIMENS FOR BREAST CANCER

3 min Chun Chao USA

Abstract 26-4-O LEANING UPON INTERNATIONAL DIRECTIVES FOR OPTIMIZATION: ANEMIA

3 min V Launay-Vacher France

Abstract 21-1-O VENOUS THROMBOLISM IN CANCER- A PROSPECTIVE STUDY 3 min Aruna Alahari Dhir India

Discussions posters 08-1-O, 26-4-O and 21-1-O 12 min Mario Dicato Luxembourg

Closure 1 min Mario Dicato Luxembourg

IN ADDITION 5 SATELLITE SYMPOSIA AND ONE SPONSORED MEET THE

EXPERT SESSION (NOT PART OF THE SCIENTIFIC PROGRAMME)

Documents

Save The Date - MASCC/ISOO 2015 Cancer Care Meetingmascc2015.kenes.com/PublishingImages/scientific-information... · CHAIRMEN: Mario Dicato (Luxembourg) and Bernardo Rapoport (South